This is a study review on FLOW, a trial assessing the impact of once-weekly semaglutide on kidney outcomes in patients with both chronic kidney disease and type 2 diabetes.
Independent commentary for the review has been provided by Dr Richard Phoon, a senior medical advisor, nephrologist, an experienced non executive director and principal investigator on several international clinical trials.
Please login below to download this issue (PDF)